< View all reports

Inflammatory Bowel Disease Market Report

Crohn’s Disease – Global Drug Forecast and Market Analysis to 2026

GlobalData estimates that by the end of 2026, the US will account for 87.2% of sales across the 7MM.

This Inflammatory Bowel Disease market report covers key topics covered including current treatment options, unmet needs and opportunities, and the drivers and barriers affecting Crohn’s Disease (CD) therapeutics sales in the 7MM. Over the course of the 10-year forecast period, sales across the global CD market will have grown steadily to reach $13.4 billion. Higher sales numbers for the US can be associated with the higher prices of pharmaceuticals and a greater diagnosed prevalence of CD in the region. As well as this, the high annual cost of therapy (ACOT) of J&J’s Stelara and the anticipated ACOT of AbbVie’s risankizumab are also present in the US market.

  • Why should you buy this report?
  • Identify companies with the most robust pipeline
  • Understand what is shaping and driving the global CD therapeutics market
  • Learn about key trends, innovative products and technologies, market segments, and companies that are likely to impact the market for CD in the future
  • Gain an understanding of the competitive landscape and analyze competitor performance
  • Identify emerging players and create effective counter-strategies to gain competitive advantage

Explore the current and future market competition in the global CD therapeutics market

On 30th July 2018, RedHill Biopharma announced top-line safety and efficacy results from the first Phase III study of RHB-104, a fixed dose antibiotic combination therapy for CD. Key opinion leaders interviewed by GlobalData recognized that development of a safe oral therapy is an important opportunity in the market, and RHB-104 has the potential to fulfil this need.

All countries in the 7 major markets, excluding Germany, will see an increase in the diagnosed prevalence cases of CD. France is likely to have the highest Annual Growth Rate of diagnosed prevalent cases of CD at 4.04%. The largest increases are expected in the US, France, and Japan, driven by both increases in the prevalence of CD and by population changes. Germany, as opposed to the other markets, will see a decrease in patient size for CD.

The high unmet need for improved medical management of perianal fistulas presents an untapped market opportunity, which could drive market growth overall. However, barriers to market growth will include pricing pressures and reimbursement issues for expensive biologic therapies. The established biologics market has created a challenging environment for new market entrants.


Purchase Today

Single user $ 10,995

Buy Now


+44 (0) 161 359 5813

Not ready to buy yet? Download our free report series guide on IBD

I consent to GlobalData collecting my details provided via this form.

You are in control of the communications you receive from us and you can update your preferences anytime to make sure you are receiving information that matters to you. Please check our GlobalData Privacy Policy to see how we protect and manage your submitted data.